Skip to main content
. 2020 Jul 13;20:649. doi: 10.1186/s12885-020-07131-6

Table 3.

Adverse drug reactions by preferred term

All patients Unmatched patients
All grades Grade ≥ 3 C20 C25
All grades Grade ≥ 3 All grades Grade ≥ 3
N 660 190 159
Patients with any ADR 511 (77.4) 409 (62.0) 149 (78.4) 116 (61.1) 142 (89.3)* 129 (81.1)
Number of ADRs 1113 644 317 177 323 211
ADRs (Grade ≥ 3 in ≥2 patients), n (%)
 Pneumonia 6 (0.9) 5 (0.8) 2 (1.1) 2 (1.1) 2 (1.3) 1 (0.6)
 Pyelonephritis 3 (0.5) 3 (0.5) 0 0 1 (0.6) 1 (0.6)
 Sepsis 4 (0.6) 4 (0.6) 2 (1.1) 2 (1.1) 1 (0.6) 1 (0.6)
 Septic shock 3 (0.5) 3 (0.5) 0 0 1 (0.6) 1 (0.6)
 Anemiaa 99 (15.0) 58 (8.8) 22 (11.6) 12 (6.3) 25 (15.7) 15 (9.4)
 Febrile neutropenia 119 (18.0) 113 (17.1) 28 (14.7) 28 (14.7) 50 (31.5) 48 (30.2)
 Leukopeniab 74 (11.2) 48 (7.3) 23 (12.1) 13 (6.8) 18 (11.3) 15 (9.4)
 Neutropeniac 324 (49.1) 263 (39.8) 103 (54.2) 81 (42.6) 98 (61.6) 88 (55.3)
 Thrombocytopeniad 77 (11.7) 36 (5.5) 29 (15.3) 11 (5.8) 16 (10.1) 7 (4.4)
 Bone marrow failure 2 (0.3) 2 (0.3) 0 0 1 (0.6) 1 (0.6)
 Decreased appetite 49 (7.4) 11 (1.7) 17 (9.0) 3 (1.6) 10 (6.3) 2 (1.3)
 Neuropathy peripheral 10 (1.5) 2 (0.3) 4 (2.1) 2 (1.1) 2 (1.3) 0
 Interstitial lung disease 8 (1.2) 7 (1.1) 1 (0.5) 0 4 (2.5) 4 (2.5)
 Pneumonitis 2 (0.3) 2 (0.3) 0 0 0 0
 Diarrhea 66 (10.0) 21 (3.2) 21 (11.1) 5 (2.6) 16 (10.1) 6 (3.8)
 Nausea 22 (3.3) 4 (0.6) 9 (4.7) 4 (2.1) 5 (3.1) 0
 Vomiting 11 (1.7) 3 (0.5) 1 (0.5) 0 3 (1.9) 2 (1.3)
 Liver disorder 3 (0.5) 3 (0.5) 0 0 1 (0.6) 1 (0.6)
 Malaise 40 (6.1) 3 (0.5) 8 (4.2) 0 9 (5.7) 0
 Pyrexia 22 (3.3) 4 (0.6) 7 (3.7) 1 (0.5) 4 (2.5) 1 (0.6)

*p < 0.01 vs C20 (Fisher’s test)

C20 20 mg/m2 cabazitaxel, C25 25 mg/m2 cabazitaxel, ADR Adverse drug reaction

aAnemia and hemoglobin decreased

bLeukopenia and white blood cell count decreased

cNeutropenia and neutrophil count decreased

dThrombocytopenia and platelet count decreased